Safety, Immunogenicity of a Novel HPBCD-Adjuvanted Influenza Vaccine
A novel quadrivalent seasonal influenza vaccine (FluCyd-vac) adjuvanted with hydroxypropropyl-b-cyclodextrin (HP-β-CD) was found to be safe and immunogenic despite containing
Tag: Clinical trial
Clinical trial: Allopregnalonone/Dexolve for Post Traumatic Stress Disorder
About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
Dec 9, 2021 – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through
Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Role of HPBCD in development of Pfizer’s novel COVID-19 oral antiviral treatment candidate
Pfizer’s breakthrough drug candidate PF-07321332 used in combination with ritonavir was poven to successfully reduce the risk of hospitalization and
Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Use of ivermectin in the treatment of Covid-19: A pilot trial
As repurposing ivermectin against Covid-19 is still in the focus of debates and as this drug can be formulated with
Aequus and reVision to Collaborate on Stargardt Disease Program using SBECD as active
Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. (“reVision”) announced a collaboration on the development of a therapy for Stargardt disease.
Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex